- Home
- SOS vs VYNE Comparison
SOS vs VYNE Comparison
Compare SOS & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SOS | VYNE |
|---|---|---|
| Founded | 2004 | 2003 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7M | 20.0M |
| IPO Year | 2005 | 2017 |
Fundamental Metrics
Financial Performance| Metric | SOS | VYNE |
|---|---|---|
| Price | $1.38 | $0.61 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 75.5K | ★ 299.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.02 | $0.29 |
| 52 Week High | $8.92 | $1.98 |
Technical Indicators
Market Signals| Indicator | SOS | VYNE |
|---|---|---|
| Relative Strength Index (RSI) | 50.69 | 61.59 |
| Support Level | $1.16 | $0.55 |
| Resistance Level | $1.56 | $0.75 |
| Average True Range (ATR) | 0.21 | 0.02 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 24.73 | 95.59 |
Price Performance
Historical ComparisonAbout SOS SOS Limited
SOS Ltd is a multifaceted company that leverages the power of data to provide marketing solutions, while also participating in the burgeoning fields of blockchain and cryptocurrency operations, as well as commodity trading. Its product offerings are diversified across four main areas: commodity trading, insurance marketing, cryptocurrency mining, and other services. The company has three reporting segments: Commodity trading, Cryptocurrency mining, and Others. Key revenue is generated from Commodity trading.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.